This article is more than 5 years old. Information may no longer be current.
ACC program to reduce CVD in type 2 diabetes gets support from industry
Click Here to Manage Email Alerts
Boehringer Ingelheim and Eli Lilly announced their support of the American College of Cardiology program to address CV risk and mortality in people with type 2 diabetes.
“The ACC encourages efforts nationwide and globally to educate and communicate to [CV] health care providers and scientists about innovative advances in [CV] risk reduction in type 2 diabetes. This is the first stage in a longer-term process of optimizing [CV] risk reduction in these complex patient populations,” Nathan D. Wong, PhD, MPH, FACC, professor and director of the Heart Disease Prevention Program at University of California, Irvine School of Medicine, said in the release.
The program takes learnings from cardiologists working with CV risk in people with type 2 diabetes and shares those discoveries with the larger community.
“Along with Lilly, Boehringer Ingelheim is proud to support the ACC in its efforts to drive quality improvement in cardiology,” Thomas Seck, MD, vice president of clinical development and medical affairs – primary care at Boehringer Ingelheim, said in the release. “Given recent advances in research on [CV] risk reduction for people with type 2 diabetes, we need a better understanding of how and when innovative health care professionals are adopting new tools in our efforts to help educate the wider cardiology community.”
Disclosures: Seck is an employee of Boehringer Ingelheim. Wong reports receiving research support from Amgen, Gilead, Pfizer and Regeneron, speaking for Regeneron and Sanofi and consulting for Pfizer.